Small-Dosing Clinical Study

Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP

Yushi Kashihara, Ichiro Ieiri, Takashi Yoshikado, Kazuya Maeda, Masato Fukae, Miyuki Kimura, Takeshi Hirota, Shunji Matsuki, Shin Irie, Noritomo Izumi, Hiroyuki Kusuhara, Yuichi Sugiyama

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aims of this study were (1) to investigate the effects of atorvastatin (10 mg, therapeutic dose) and grapefruit juice (GFJ), inhibitors of OATP2B1, on the pharmacokinetics of substrates for OATP2B1 and BCRP under oral small-dosing conditions (300 μg sulfasalazine, 250 μg rosuvastatin, 300 μg glibenclamide, 1200 μg celiprolol, and 600 μg sumatriptan), and (2) to evaluate the contribution of SLCO2B1*3 and ABCG2 c.421C>A polymorphisms to the pharmacokinetics of the 5 test drugs in 23 healthy volunteers. In the 3 phases, the test drugs were administered to volunteers with either water (control phase), atorvastatin, or GFJ. GFJ but not atorvastatin reduced the exposure of the test drugs significantly more than the control phase, suggesting that all 5 test drugs are substrates for OATP2B1. The SLCO2B1*3 genotype had no effect on the pharmacokinetics of the test drugs. In contrast, the exposure of sulfasalazine and rosuvastatin was significantly higher in ABCG2 421C/A than in ABCG2 421C/C individuals at all 3 phases, even under small-dosing conditions.

Original languageEnglish
Pages (from-to)2688-2694
Number of pages7
JournalJournal of Pharmaceutical Sciences
Volume106
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Citrus paradisi
Pharmacogenetics
Pharmacokinetics
Sulfasalazine
Pharmaceutical Preparations
Celiprolol
Sumatriptan
Glyburide
Volunteers
Healthy Volunteers
Genotype
Clinical Studies
Atorvastatin Calcium
Water

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Small-Dosing Clinical Study : Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. / Kashihara, Yushi; Ieiri, Ichiro; Yoshikado, Takashi; Maeda, Kazuya; Fukae, Masato; Kimura, Miyuki; Hirota, Takeshi; Matsuki, Shunji; Irie, Shin; Izumi, Noritomo; Kusuhara, Hiroyuki; Sugiyama, Yuichi.

In: Journal of Pharmaceutical Sciences, Vol. 106, No. 9, 01.09.2017, p. 2688-2694.

Research output: Contribution to journalArticle

Kashihara, Yushi ; Ieiri, Ichiro ; Yoshikado, Takashi ; Maeda, Kazuya ; Fukae, Masato ; Kimura, Miyuki ; Hirota, Takeshi ; Matsuki, Shunji ; Irie, Shin ; Izumi, Noritomo ; Kusuhara, Hiroyuki ; Sugiyama, Yuichi. / Small-Dosing Clinical Study : Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. In: Journal of Pharmaceutical Sciences. 2017 ; Vol. 106, No. 9. pp. 2688-2694.
@article{022eab6ce34943e89cf8a9016b3df789,
title = "Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP",
abstract = "The aims of this study were (1) to investigate the effects of atorvastatin (10 mg, therapeutic dose) and grapefruit juice (GFJ), inhibitors of OATP2B1, on the pharmacokinetics of substrates for OATP2B1 and BCRP under oral small-dosing conditions (300 μg sulfasalazine, 250 μg rosuvastatin, 300 μg glibenclamide, 1200 μg celiprolol, and 600 μg sumatriptan), and (2) to evaluate the contribution of SLCO2B1*3 and ABCG2 c.421C>A polymorphisms to the pharmacokinetics of the 5 test drugs in 23 healthy volunteers. In the 3 phases, the test drugs were administered to volunteers with either water (control phase), atorvastatin, or GFJ. GFJ but not atorvastatin reduced the exposure of the test drugs significantly more than the control phase, suggesting that all 5 test drugs are substrates for OATP2B1. The SLCO2B1*3 genotype had no effect on the pharmacokinetics of the test drugs. In contrast, the exposure of sulfasalazine and rosuvastatin was significantly higher in ABCG2 421C/A than in ABCG2 421C/C individuals at all 3 phases, even under small-dosing conditions.",
author = "Yushi Kashihara and Ichiro Ieiri and Takashi Yoshikado and Kazuya Maeda and Masato Fukae and Miyuki Kimura and Takeshi Hirota and Shunji Matsuki and Shin Irie and Noritomo Izumi and Hiroyuki Kusuhara and Yuichi Sugiyama",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.xphs.2017.03.010",
language = "English",
volume = "106",
pages = "2688--2694",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Small-Dosing Clinical Study

T2 - Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP

AU - Kashihara, Yushi

AU - Ieiri, Ichiro

AU - Yoshikado, Takashi

AU - Maeda, Kazuya

AU - Fukae, Masato

AU - Kimura, Miyuki

AU - Hirota, Takeshi

AU - Matsuki, Shunji

AU - Irie, Shin

AU - Izumi, Noritomo

AU - Kusuhara, Hiroyuki

AU - Sugiyama, Yuichi

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The aims of this study were (1) to investigate the effects of atorvastatin (10 mg, therapeutic dose) and grapefruit juice (GFJ), inhibitors of OATP2B1, on the pharmacokinetics of substrates for OATP2B1 and BCRP under oral small-dosing conditions (300 μg sulfasalazine, 250 μg rosuvastatin, 300 μg glibenclamide, 1200 μg celiprolol, and 600 μg sumatriptan), and (2) to evaluate the contribution of SLCO2B1*3 and ABCG2 c.421C>A polymorphisms to the pharmacokinetics of the 5 test drugs in 23 healthy volunteers. In the 3 phases, the test drugs were administered to volunteers with either water (control phase), atorvastatin, or GFJ. GFJ but not atorvastatin reduced the exposure of the test drugs significantly more than the control phase, suggesting that all 5 test drugs are substrates for OATP2B1. The SLCO2B1*3 genotype had no effect on the pharmacokinetics of the test drugs. In contrast, the exposure of sulfasalazine and rosuvastatin was significantly higher in ABCG2 421C/A than in ABCG2 421C/C individuals at all 3 phases, even under small-dosing conditions.

AB - The aims of this study were (1) to investigate the effects of atorvastatin (10 mg, therapeutic dose) and grapefruit juice (GFJ), inhibitors of OATP2B1, on the pharmacokinetics of substrates for OATP2B1 and BCRP under oral small-dosing conditions (300 μg sulfasalazine, 250 μg rosuvastatin, 300 μg glibenclamide, 1200 μg celiprolol, and 600 μg sumatriptan), and (2) to evaluate the contribution of SLCO2B1*3 and ABCG2 c.421C>A polymorphisms to the pharmacokinetics of the 5 test drugs in 23 healthy volunteers. In the 3 phases, the test drugs were administered to volunteers with either water (control phase), atorvastatin, or GFJ. GFJ but not atorvastatin reduced the exposure of the test drugs significantly more than the control phase, suggesting that all 5 test drugs are substrates for OATP2B1. The SLCO2B1*3 genotype had no effect on the pharmacokinetics of the test drugs. In contrast, the exposure of sulfasalazine and rosuvastatin was significantly higher in ABCG2 421C/A than in ABCG2 421C/C individuals at all 3 phases, even under small-dosing conditions.

UR - http://www.scopus.com/inward/record.url?scp=85018641327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018641327&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2017.03.010

DO - 10.1016/j.xphs.2017.03.010

M3 - Article

VL - 106

SP - 2688

EP - 2694

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 9

ER -